ZIMLAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 34/100 — Quality 28 · Valuation 2 · Momentum 100
| Share price | ₹125.50 |
| Market cap | ₹618 Cr |
| P/E ratio | 96.8 |
| P/B ratio | 2.1 |
| ROE | 2.6% |
| ROCE | 5.8% |
| Book value | ₹55.35 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹374 Cr | ₹6 Cr | 8.0% |
| 2025 | ₹379 Cr | ₹12 Cr | 12.0% |
| 2024 | ₹367 Cr | ₹17 Cr | 11.0% |
| 2023 | ₹399 Cr | ₹24 Cr | 13.0% |
| 2022 | ₹333 Cr | ₹15 Cr | 12.0% |
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. Th